Skip to content
value.today

Stereotaxis, Inc.

STXS
$92 Mmarket cap on Oct 30, 2026-39.2% since Jan 2024
Compare
World rank
#19,063
Revenue
$32 M
For year ending December-2025
Net income
$-22 M
-66.8% margin
SEC filing
Employees
131
As of December 31, 2025
SEC filing

Stereotaxis, Inc. in brief

Stereotaxis, Inc. is a listed company in the Medical Instruments industry, based in St.Louis, Missouri, USA. It was founded in 1990. Its market value was $92 M on 30 October 2026, which makes it the 19,063rd largest listed company in the world and the 3,558th largest in the USA on this site. In the year to December 2025 it had sales of $32 M and a net loss of $22 M. It employs about 131 people and David Fischel is its chief executive. Its largest product and service lines by sales in 2025 were Disposables Service and Accessories (68%) and Systems (32%). By market, the largest shares of its 2025 sales came from USA (40%). Its shares trade under the symbol STXS (NYSE).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Stereotaxis, Inc.

These statements relate to future events or future financial performance, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “could”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue”, or the negative of such terms or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. These statements are only predictions.

From the company's annual report filed with the US SEC: read the report

Stereotaxis, Inc. timeline

3 events, 1990–2021
  1. 1990
  2. 🏁
    · approximate
    Founded
  3. 2004
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2021
  6. 💰
    Record revenue of $35 million
    FY2021, the highest of the 8 years on record.

Events of Stereotaxis, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$124 M$248 M$372 M$496 M2020202120222023202420252026

World rank over time

▼ down 6,046 places since 2020
2020-01-01: #13056#13,05620202021-01-01: #12619#12,61920212022-01-07: #13960#13,96020222022-12-25: #19504#19,50420222023-07-30: #20572#20,57220232024-01-05: #19383#19,38320242026-03-08: #9057#9,05720262026-08-01: #16446#16,44620262026-10-14: #18599#18,59920262026-10-30: #19102#19,1022026

Rank in USA: #2,778 (Jan 2020) · #2,986 (Jan 2021) · #3,014 (Jan 2022) · #3,937 (Dec 2022) · #4,026 (Jul 2023) · #3,443 (Jan 2024) · #1,725 (Mar 2026) · #3,278 (Aug 2026) · #3,465 (Oct 2026) · #3,562 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
3.1×
Price / book
6.8×
Free cash flow yield
-15.0%
Net margin (TTM)
-74.2%
Operating margin
-68.3%
Return on equity
-165.6%
Liabilities / assets
64.2%
Net debt
$-43M
Revenue growth
+20.3%
R&D / revenue
29.0%
Revenue per employee
$247 K
Profit per employee
$-165 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $29M, net income $0M$29MFY18Fiscal year ending Dec 2019: revenue $29M, net income $-5M$29MFY19Fiscal year ending Dec 2020: revenue $27M, net income $-7M$27MFY20Fiscal year ending Dec 2021: revenue $35M, net income $-11M$35MFY21Fiscal year ending Dec 2022: revenue $28M, net income $-18M$28MFY22Fiscal year ending Dec 2023: revenue $27M, net income $-21M$27MFY23Fiscal year ending Dec 2024: revenue $27M, net income $-24M$27MFY24Fiscal year ending Dec 2025: revenue $32M, net income $-22M$32MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$32M+20.3%$-22M$-22M-66.8%
Dec 2024$27M+0.6%$-25M$-24M-89.3%
Dec 2023$27M-4.9%$-22M$-21M-77.4%
Dec 2022$28M-19.6%$-19M$-18M-65.0%
Dec 2021$35M+31.5%$-13M$-11M-30.6%
Dec 2020$27M-7.9%$-7M$-7M-25.0%
Dec 2019$29M-1.5%$-5M$-5M-15.9%
Dec 2018$29M—$-2M$0M0.4%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-14M$0M$-14M$-0.25—
Dec 2024$-9M$0M$-9M$-0.30—
Dec 2023$-9M$0M$-10M$-0.27—
Dec 2022$-8M$2M$-11M$-0.26—
Dec 2021$-3M$1M$-4M$-0.16—
Dec 2020$-4M$0M$-4M$-0.11—
Dec 2019$-5M$0M$-5M$-0.10—
Dec 2018$-3M$0M$-3M$-0.03—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$30M
Net income, trailing 12 months
$-22M
RevenueNet income
Three months to Sep 2024: revenue $9M, net income $-6M$9MSep ’24Three months to Dec 2024 (from the annual report): revenue $6M, net income $-8M$6MDec ’24Three months to Mar 2025: revenue $7M, net income $-6M$7MMar ’25Three months to Jun 2025: revenue $9M, net income $-4M$9MJun ’25Three months to Sep 2025: revenue $7M, net income $-6M$7MSep ’25Three months to Dec 2025 (from the annual report): revenue $9M, net income $-6M$9MDec ’25Three months to Mar 2026: revenue $6M, net income $-6M$6MMar ’26Three months to Jun 2026: revenue $8M, net income $-4M$8MJun ’26

Latest quarter to Jun 2026: revenue $8M (-12.8% on a year earlier), net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Stereotaxis, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$32 M
Operating income
$-22 M
Net income
$-22 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$52 M
Total liabilities
$34 M
Total equity
$13 M

As of December-2025

Top 100 institutional investors in Stereotaxis, Inc.#

As of Sep 30, 2026
102 institutions held 41.2 M shares (about 41.1% of the shares outstanding) on Sep 30, 2026. The ten largest hold 33.7%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Stereotaxis, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1DAFNA Capital Management LLC13,680,5540 (0.00%)13.65%$17 MNov 16, 2026
2BlackRock, Inc.4,384,200-12,635 (-0.29%)4.38%$5 MNov 13, 2026
3Lagoda Investment Management, L.P.3,981,900-140,700 (-3.41%)3.97%$5 MNov 16, 2026
4Vanguard Capital Management LLC3,009,889-34,931 (-1.15%)3.00%$4 MNov 13, 2026
5Arbiter Partners Capital Management LLC2,883,856-2,883,856 (-50.00%)2.88%$4 MNov 12, 2026
6Geode Capital Management, LLC1,904,750+9,507 (+0.50%)1.90%$2 MNov 6, 2026
7Archon Capital Management LLC1,226,0440 (0.00%)1.22%$2 MNov 16, 2026
8Warberg Asset Management LLC1,131,371+22,482 (+2.03%)1.13%$1 MNov 2, 2026
9State Street Corp910,966-5,814 (-0.63%)0.91%$1 MNov 12, 2026
10Integrity Alliance, LLC.699,023New0.70%$1 MOct 29, 2026
11AlphaCentric Advisors LLC600,0000 (0.00%)0.60%$1 MNov 3, 2026
12Vanguard Fiduciary Trust Co587,476-1,634 (-0.28%)0.59%$1 MNov 13, 2026
13Northern Trust Corp561,854+32,159 (+6.07%)0.56%$1 MNov 16, 2026
14Bank Julius Baer & Co. Ltd, Zurich540,5300 (0.00%)0.54%$1 MOct 29, 2026
15Vanguard Portfolio Management LLC478,334+14,754 (+3.18%)0.48%$1 MNov 13, 2026
16Sequoia Financial Advisors, LLC380,243-1,112 (-0.29%)0.38%$0 MNov 13, 2026
17UBS Group AG372,228+120,895 (+48.10%)0.37%$0 MNov 10, 2026
18Goldman Sachs Group Inc329,420+94,449 (+40.20%)0.33%$0 MNov 16, 2026
19Bank of New York Mellon Corp310,068+98,427 (+46.51%)0.31%$0 MNov 5, 2026
20Prescott Group Capital Management, L.L.C.237,4950 (0.00%)0.24%$0 MOct 30, 2026
21Independent Advisor Alliance212,985+4,500 (+2.16%)0.21%$0 MNov 10, 2026
22Charles Schwab Investment Management Inc174,215+30,049 (+20.84%)0.17%$0 MNov 16, 2026
23Royal Bank Of Canada173,757+8,394 (+5.08%)0.17%$0 MNov 16, 2026
24Price T Rowe Associates Inc /MD/172,867+32,165 (+22.86%)0.17%$0 MNov 16, 2026
25Morgan Stanley172,743-159,364 (-47.99%)0.17%$0 MNov 13, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Stereotaxis, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Bank Of America Corp /de/145,081+27,763 (+23.66%)0.14%$0 MNov 16, 2026
27Bridgeway Capital Management, LLC139,330-34,445 (-19.82%)0.14%$0 MNov 16, 2026
28GMT Capital Corp126,5810 (0.00%)0.13%$0 MNov 16, 2026
29Empowered Funds, LLC125,030New0.12%$0 MNov 13, 2026
30Nuveen, LLC113,836+39,846 (+53.85%)0.11%$0 MNov 10, 2026
31Barclays PLC82,504+15,564 (+23.25%)0.08%$0 MNov 6, 2026
32Leonteq Securities AG74,9940 (0.00%)0.07%$0 MOct 29, 2026
33AQR Capital Management LLC70,582-126,040 (-64.10%)0.07%$0 MNov 16, 2026
34HSBC Holdings PLC68,6050 (0.00%)0.07%$0 MNov 16, 2026
35Susquehanna International Group, LLP60,748+10,189 (+20.15%)0.06%$0 MNov 16, 2026
36Deutsche Bank AG\59,338-8,199 (-12.14%)0.06%$0 MNov 6, 2026
37R Squared Ltd49,784+36,057 (+262.67%)0.05%$0 MNov 6, 2026
38Quadrature Capital Ltd49,267+38,561 (+360.18%)0.05%$0 MNov 13, 2026
39Cetera Investment Advisers48,813New0.05%$0 MNov 13, 2026
40Invesco Ltd.47,941+9,371 (+24.30%)0.05%$0 MNov 12, 2026
41Rhumbline Advisers45,308-84,734 (-65.16%)0.05%$0 MNov 10, 2026
42TCFG Investment Advisors, LLC41,015-28,000 (-40.57%)0.04%$0 MOct 20, 2026
43Verition Fund Management LLC35,0000 (0.00%)0.03%$0 MNov 13, 2026
44Vanguard Global Advisers, LLC34,663+271 (+0.79%)0.03%$0 MNov 13, 2026
45Jpmorgan Chase & Co34,327+4,030 (+13.30%)0.03%$0 MNov 12, 2026
46MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.33,068+1,675 (+5.34%)0.03%$0 MNov 16, 2026
47Cherry Creek Investment Advisors, Inc.28,027-14,575 (-34.21%)0.03%$0 MOct 14, 2026
48Thompson Davis & Co., Inc.27,9990 (0.00%)0.03%$0 MNov 5, 2026
49Forum Financial Management, LP26,618+100 (+0.38%)0.03%$0 MOct 16, 2026
50Russell Investments Group, Ltd.26,411+9,003 (+51.72%)0.03%$0 MNov 6, 2026
51Vanguard Personalized Indexing Management, LLC26,145New0.03%$0 MNov 16, 2026
52Wells Fargo & Company/mn22,720-39,471 (-63.47%)0.02%$0 MNov 16, 2026
53Summit Asset Management, LLC22,5000 (0.00%)0.02%$0 MNov 5, 2026
54Alliancebernstein L.P.21,7800 (0.00%)0.02%$0 MNov 16, 2026
55Choreo, LLC21,688+8,630 (+66.09%)0.02%$0 MOct 28, 2026
56Wealthspire Advisors, LLC20,000-4,000 (-16.67%)0.02%$0 MNov 13, 2026
57Z3 Capital Partners, LLC20,000-5,000 (-20.00%)0.02%$0 MNov 10, 2026
58BNP Paribas Financial Markets19,620+8,467 (+75.92%)0.02%$0 MNov 12, 2026
59Raymond James Financial Inc19,134+101 (+0.53%)0.02%$0 MNov 12, 2026
60PNC Financial Services Group, Inc.18,611+1,307 (+7.55%)0.02%$0 MNov 6, 2026
61Police & Firemen's Retirement System of New Jersey17,9970 (0.00%)0.02%$0 MNov 9, 2026
62Investors Research Corp17,9500 (0.00%)0.02%$0 MOct 7, 2026
63Squarepoint Ops LLC14,503New0.01%$0 MNov 9, 2026
64LPL Financial LLC13,930+3,000 (+27.45%)0.01%$0 MNov 6, 2026
65WealthPLAN Partners, LLC13,6650 (0.00%)0.01%$0 MOct 15, 2026
66Envestnet Asset Management Inc12,291-79,287 (-86.58%)0.01%$0 MNov 16, 2026
67Renaissance Technologies LLC10,900-4,500 (-29.22%)0.01%$0 MNov 12, 2026
68Benin Management CORP10,5000 (0.00%)0.01%$0 MOct 22, 2026
69Cerity Partners LLC10,369-3,203 (-23.60%)0.01%$0 MNov 13, 2026
70FMR LLC10,293-14,507 (-58.50%)0.01%$0 MNov 10, 2026
71Roble, Belko & Company, Inc10,0000 (0.00%)0.01%$0 MNov 9, 2026
72Pasadena Private Wealth, LLC10,0000 (0.00%)0.01%$0 MNov 10, 2026
73Tower Research Capital LLC (TRC)8,815-2,778 (-23.96%)0.01%$0 MNov 16, 2026
74Legal & General Group Plc7,8190 (0.00%)0.01%$0 MNov 16, 2026
75New York State Common Retirement Fund7,6000 (0.00%)0.01%$0 MNov 17, 2026
76Global Retirement Partners, LLC7,562New0.01%$0 MNov 10, 2026
77Rockefeller Capital Management L.P.5,950+1,000 (+20.20%)0.01%$0 MNov 13, 2026
78Ameritas Investment Partners, Inc.5,3700 (0.00%)0.01%$0 MNov 13, 2026
79Farther Finance Advisors, LLC4,157+60 (+1.46%)0.00%$0 MOct 8, 2026
80Citigroup Inc3,379-28,619 (-89.44%)0.00%$0 MNov 4, 2026
81Group One Trading LLC2,9360 (0.00%)0.00%$0 MNov 10, 2026
82Nisa Investment Advisors, LLC2,7940 (0.00%)0.00%$0 MOct 20, 2026
83Bell Investment Advisors, Inc2,652New0.00%$0 MOct 29, 2026
84Smartleaf Asset Management LLC2,367-1,113 (-31.98%)0.00%$0 MNov 10, 2026
85Sterling Capital Management LLC2,236+2,052 (+1115.22%)0.00%$0 MOct 22, 2026
86Bare Financial Services, Inc2,214New0.00%$0 MNov 4, 2026
87Osaic Holdings, Inc.1,889+629 (+49.92%)0.00%$0 MNov 12, 2026
88Hickory Point Bank & Trust1,5000 (0.00%)0.00%$0 MOct 1, 2026
89Simplex Trading, LLC1,364-1,516 (-52.64%)0.00%$0 MNov 4, 2026
90Avion Wealth1,0000 (0.00%)0.00%$0 MNov 4, 2026
91California State Teachers Retirement System8710 (0.00%)0.00%$0 MNov 13, 2026
92GAMMA Investing LLC550New0.00%$0 MOct 8, 2026
93Arax Advisory Partners480-940 (-66.20%)0.00%$0 MNov 12, 2026
94Allworth Financial LP205-385 (-65.25%)0.00%$0 MNov 17, 2026
95EverSource Wealth Advisors, LLC177-98 (-35.64%)0.00%$0 MNov 4, 2026
96James T. Borello RIA132New0.00%$0 MOct 16, 2026
97Clark Wealth Partners1000 (0.00%)0.00%$0 MOct 19, 2026
98Fortitude Family Office, LLC66-18 (-21.43%)0.00%$0 MOct 14, 2026
99IFP Advisors, Inc24+10 (+71.43%)0.00%$0 MOct 16, 2026
100Essential Partners LLC9-191 (-95.50%)0.00%$0 MOct 14, 2026

All 102 institutional investors, with who bought and sold →

Mutual funds holding Stereotaxis, Inc.#

58 funds hold shares worth $14 M (about 8.5% of the company). Since their previous reports 23 added shares and 15 sold, buying $0 M net.
Mutual funds holding Stereotaxis, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.98 M$3 M2.0%<0.01%+3.6%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.63 M$3 M1.6%<0.01%+13%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.985,512$2 M0.98%<0.01%−2.2%Jun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors640,255$1 M0.64%<0.01%+41%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC733,836$1 M0.73%<0.01%+21%Jul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC437,373$1 M0.44%<0.01%−0.8%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.318,322$1 M0.32%<0.01%+6.5%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors228,492$0 M0.23%0.03%+46%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC147,741$0 M0.15%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC124,229$0 M0.12%<0.01%+6.6%May 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC127,100$0 M0.13%0.15%no changeJun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.164,422$0 M0.16%<0.01%+27%Jul 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.109,607$0 M0.11%<0.01%+71%Jun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC100,304$0 M0.10%<0.01%+12%Jun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC63,199$0 M0.06%<0.01%+42%Jun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC63,157$0 M0.06%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.52,938$0 M0.05%<0.01%+3.2%May 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC73,990$0 M0.07%<0.01%no changeJul 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation43,500$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.40,691$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.34,931$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC43,108$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company23,285$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.26,120$0 M0.03%<0.01%−27%Jun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC32,568$0 M0.03%<0.01%+22%Jul 31, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC28,245$0 M0.03%<0.01%−1.9%Jul 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.20,200$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC16,233$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC15,379$0 M0.02%0.01%+39%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC13,764$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS13,190$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC12,390$0 M0.01%<0.01%+48%Jun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC14,560$0 M0.01%<0.01%+18%Jul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC9,899$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC9,390$0 M<0.01%<0.01%+74%Jun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.8,864$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC7,720$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.6,965$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.9,499$0 M<0.01%<0.01%+7.1%Jul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC6,854$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC9,381$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC6,276$0 M<0.01%<0.01%+67%Jun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.5,369$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC5,944$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management5,370$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC6,634$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC4,743$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.3,268$0 M<0.01%<0.01%+4.5%May 31, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS4,929$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC2,925$0 M<0.01%<0.01%+11%May 31, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC2,874$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC4,266$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC2,311$0 M<0.01%<0.01%−38%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC2,288$0 M<0.01%<0.01%−39%May 31, 2026
🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC1,846$0 M<0.01%<0.01%−5.0%May 31, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC2,064$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.1,739$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC853$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 58 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Stereotaxis, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$136 K
4 purchases, 3 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$136 K
open market only
Insiders on file
30
since
$136 K$0Nov 2023: bought $112 K (9 trades), sold $0 (0 trades)Nov 23Dec 2023: bought $19 K (1 trades), sold $0 (0 trades)DecMay 2024: bought $19 K (3 trades), sold $0 (0 trades)MayJun 2024: bought $13 K (1 trades), sold $0 (0 trades)JunAug 2024: bought $18 K (3 trades), sold $0 (0 trades)AugMar 2025: bought $114 K (3 trades), sold $0 (0 trades)MarNov 2025: bought $67 K (2 trades), sold $0 (0 trades)NovNov 2026: bought $136 K (4 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Stereotaxis, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Arun Swarup MenawatDirectorBuy+121,561$0.823$100 K1.16 MForm 4
filed David BenferDirectorBuyindirect+30,000$0.829$25 K240,255Form 4
filed Paul J. IsaacDirectorBuyindirect+300$0.800$2402.80 MForm 4
filed Paul J. IsaacDirectorBuyindirect+13,000$0.820$11 K2.80 MForm 4
filed Nathan FischelDirector, 10% ownerGrant or award+43,103——720,775Form 4
filed Arun Swarup MenawatDirectorGrant or award+43,103——1.04 MForm 4
filed Myriam CuretDirectorGrant or award+43,103——435,161Form 4
filed Ross B. LevinDirectorGrant or award+43,103——621,248Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Stereotaxis, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
5.6 M
8.4 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-10 reverse split

Fails to deliver

  • : 25,500 shares at $0.91
  • : 1,349 shares at $1.00
  • : 258 shares at $0.99
  • : 20 shares at $1.05
  • : 11 shares at $1.06

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Stereotaxis, Inc. scorecard#

Passes 2 of the 22 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median6.8×Price to book 6.8× against Medical Instruments's median of 3.9×.
    • ✗Price to sales below its peers' median3.0×Price to sales 3.0× against Medical Instruments's median of 3.0×.
    • ✗Free cash flow yield above 5%-15.0%Free cash flow is -15.0% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 6
    • ✓Revenue grew in the newest year20.3%Revenue up 20.3% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years4.8%4.8% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median4.8%4.8% a year against Medical Instruments's median of 5.0% (37 companies).
    • ✗Earnings per share grew in the newest year-0.25 vs -0.30Diluted EPS -0.25 in fiscal 2025 against -0.30 the year before (report's currency).
    • ✗Net income higher than five years earlier-$22 M-$22 M in fiscal 2025 against -$7 M in 2020.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
  • Profitability0 of 5
    • ✗Profitable in the newest year-$22 MNet income -$22 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-68.3%-68.3% against Medical Instruments's median of 7.2% (46 companies).
    • ✗Return on equity above 15%-221.3%-221.3% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-68.3%-68.3% in fiscal 2025 against -66.7% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities1.5×Current ratio 1.51 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-14.50Z-score -14.50 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 3
    • ✗Pays a dividendNoNo dividends in fiscal 2025.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year6.8%Diluted shares up 6.8% in fiscal 2025.
    • ✗Dividends and buybacks above 3% of the market value0.0%Dividends and buybacks were 0.0% of the market value.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Medical Instruments, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Stereotaxis, Inc.'s statements, beside the median of Medical Instruments.

Stereotaxis, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-68.3%7.2%
Net margin-66.8%3.8%
Return on equity-221.3%3.5%
Revenue growth, 3 years a year4.8%5.0%
Revenue growth20.3%8.9%
Free cash flow margin-42.5%6.3%

4of 8on the Piotroski tests of financial strength

  • Net loss of $22 million, the 7th loss-making year in a row.
  • Free cash flow was negative: -$14 million.
  • The share count rose 6.8% in the year.
  • Receivables grew 53% while revenue grew 20%: customers are paying later, or sales were booked ahead of cash.

Stereotaxis, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Stereotaxis, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue3227272835r2729293132
Cost of revenue1512129.712r7.76.15.7117.5
Gross profit1715151823r1923242025
Research and development9.49.8101110r8.19.08.26.7r5.5
Selling and marketing1212121212r11131314r15
General and administrative1817141414r6.45.84.96.0r10
Operating expenses3939373736r2628262631
Operating income−22−25−22−19−13r−6.7−4.8−2.5−5.9−6.4
Interest and finance income————0.1————0.0
Interest expense and finance costs———————0.00.22.5r
Net interest income0.50.71.10.5−0.0r0.10.2−0.0——
Other non-operating income (expense)0.0—0.0————2.60.2−2.0
Net income attributable to shareholders−22−24−21−18−11r−6.6−4.60.1−5.9−5.3
Earnings per share, basic-0.25-0.30-0.27-0.26-0.16-0.11-0.10-0.03-0.32-0.54
Earnings per share, diluted-0.25-0.30-0.27-0.26-0.16-0.11-0.10-0.03-0.32-0.54
Shares, weighted average (basic)91858176767363522322
Shares, weighted average (diluted)91858176767363522322
Balance sheet
Cash and cash equivalents1312208.639r4430113.78.5
Short-term investments00—20——————
Receivables5.83.83.85.15.4r3.55.35.04.34.7
Inventory9.68.38.47.94.4r3.31.81.21.15.4
Other current assets0.71.80.71.32.4r1.71.51.00.80.9
Current assets3426334351r5339189.919
Property, plant and equipment3.03.63.33.82.6r0.20.30.30.61.1
Right-of-use (leased) assets4.95.55.05.45.7r2.24.3———
Goodwill3.83.8————————
Other intangible assets6.47.4——————0.20.4
Total assets5247425361r5544191121
Accounts payable4.85.73.23.34.2r1.62.11.71.72.6
Current liabilities2222131413r1412103036
Long-term debt—————1.0————
Lease liabilities (non-current)4.85.45.15.55.8r—2.1———
Total liabilities3435202122r1515113136
Retained earnings−583−562−538−517−499r−488−481−477−477−471
Shareholders' equity136.1162634r35r231.3−27−21
Total liabilities and equity5247425361r5544191121
Cash-flow statement
Share-based compensation9.91011119.4r3.21.30.60.81.4
Cash from operating activities−14−8.5−9.1−8.4−2.9r−3.5−4.6−2.5−4.7−6.6
Capital expenditure−0.1−0.0−0.4−2.4−1.4r−0.1−0.0−0.3−0.1−0.4
Cash from investing activities−0.10.120−22−1.4r−0.1−0.0−0.3−0.1−0.4
Shares issued160.30.10.20.5r15240.10.023
Dividends paid000000——00
Cash from financing activities150.30.10.20.5r17249.9−0.19.9
Change in cash1.0−8.111−30−3.8r14197.1−4.82.9
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Stereotaxis, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Disposables Service and Accessories$22 M68%
  • Systems$10 M32%

Countries and regions

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Stereotaxis, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$64 K
David Fischel
Other top executives, average
$326 K
the CEO earned 0.2× this
$100 invested is now
$111
Stereotaxis, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025David Fischel$64 K−$2.0 M$326 K$111
2024David Fischel$62 K$3.7 M$340 K$112
2023David Fischel$62 K−$4.3 M$324 K$85

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Stereotaxis, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 1 · Material agreement 5 · New debt 1 · Unregistered share sale 5 · Shareholder vote 3 · Results announced 14

Stereotaxis, Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreementNew debtUnregistered share saleResults announced8-K
Results announced8-K
Unregistered share sale8-K
Shareholder vote8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Unregistered share sale8-K
Directors and officers8-K
Material agreementUnregistered share saleShareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Stereotaxis, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2024$3 MPrivate placement after listing$2 to $10 million1equitySEC
Aug 2019$25 MPrivate placement after listing$10 to $50 million6equitySEC
Sep 2016$24 MPrivate placement after listing$10 to $50 million12equity, optionsSEC
May 2012$8 MPrivate placement after listing$2 to $10 million9debt, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Stereotaxis, Inc.#

1 labor condition applications certified in fiscal 2022 for 1 positions, at a median wage of $120 K a year.

Certified, FY2022
1
#2,026 among companies on value.today
Worker positions
1
Median wage offered
$120 K
a year, full-time
Applications filed
1
Stereotaxis, Inc.: most frequent H-1B job titles in fiscal 2022
Job titlePositionsMedian wage offered
Sr. Principal Electrical EngineerElectrical Engineers1$120 K

Where: St. Louis, MO 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Stereotaxis, Inc.

How Stereotaxis, Inc. compares in Medical Instruments

  • Market cap$92 M · higher than 16% of 116
  • Revenue$32 M · higher than 12% of 120
  • Net margin-74.2% · higher than 4% of 114
  • Revenue growth20.3% · higher than 81% of 49
  • Price / sales3.0× · lower than 50% of 85
  • Price / book6.8× · lower than 19% of 84
  • FCF yield-15.0% · higher than 13% of 39

Peer comparison · Medical Instruments

CompanyMarket capP/ENet marginRev. growth
Stereotaxis, Inc.🇺🇸$92 M—-74.2%+20.3%
Intuitive Surgical, Inc.🇺🇸$155.6 B52.6×25.5%+20.5%
EssilorLuxottica S.A.🇫🇷$88.0 B32.1×8.1%+4.5%
HOYA Corporation🇯🇵$56.2 B32.8×25.4%—
Becton, Dickinson and Company🇺🇸$54.0 B57.4×4.2%+8.2%
Alcon Inc.🇨🇭$37.1 B37.9×9.4%+4.9%
ResMed Inc.🇺🇸$35.3 B22.1×27.8%+9.8%
West Pharmaceutical Services, Inc.🇺🇸$27.1 B42.4×18.8%+6.3%
Terumo Corporation🇯🇵$24.9 B27.0×12.0%—

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Stereotaxis, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Stereotaxis, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Stereotaxis, Inc.? Suggest a correction